Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lynparza's Wider Prospects Boosted By Late-Stage Breast Cancer Study

Executive Summary

Hopes for wider use of AstraZeneca Lynparza (olaparib) were boosted by Phase III data showing improved survival rates in patients with a certain type of breast cancer who used the PARP inhibitor compared with chemotherapy alone.

Advertisement

Related Content

AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC
AbbVie Makes Further Inroads In Oncology As Humira Loss Looms
Lynparza May Still Rival Tesaro's Niraparib In Ovarian Cancer Therapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register